Sponsor:
Riboscience, LLC.
Code:
NCT07175441
Conditions
Advanced Unresectable Hepatocellular Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RBS2418
STRIDE (durvalumab + tremelimumab)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-01. This information was provided to ClinicalTrials.gov by Riboscience, LLC. on 2025-12-24.